Regeneron Pharmaceuticals, Inc. (REGN) Holdings Lifted by Rhumbline Advisers

Rhumbline Advisers raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 135,284 shares of the biopharmaceutical company’s stock after buying an additional 2,030 shares during the quarter. Rhumbline Advisers owned about 0.13% of Regeneron Pharmaceuticals worth $60,488,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Alpha Windward LLC grew its holdings in Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 1 shares in the last quarter. Regentatlantic Capital LLC grew its holdings in Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5 shares in the last quarter. Capital Planning Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 12 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 12 shares in the last quarter. Finally, Princeton Capital Management Inc. grew its holdings in Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 15 shares in the last quarter. 67.80% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Holdings Lifted by Rhumbline Advisers” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/14/regeneron-pharmaceuticals-inc-regn-holdings-lifted-by-rhumbline-advisers.html.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down $4.60 on Tuesday, hitting $389.02. The stock had a trading volume of 284,715 shares, compared to its average volume of 902,722. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55. The stock has a market capitalization of $43,346.87, a PE ratio of 35.03, a PEG ratio of 1.56 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same period in the previous year, the firm earned $3.13 earnings per share. The business’s revenue was up 23.0% compared to the same quarter last year. analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.77 earnings per share for the current fiscal year.

REGN has been the subject of a number of recent analyst reports. Bank of America Corporation reaffirmed a “buy” rating and set a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. BMO Capital Markets reaffirmed a “market perform” rating and set a $484.00 target price (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Barclays PLC reaffirmed an “equal weight” rating and set a $450.00 target price (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, July 22nd. Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, July 28th. Finally, Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a research report on Tuesday, August 1st. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $481.49.

In related news, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Insiders have sold 88,942 shares of company stock worth $42,064,076 over the last three months. Insiders own 10.80% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply